Dasatinib + quercetin

1. Dasatinib + quercetin decreases cellular senescence in humans.

   Human trialfibrotic MASHliverdasatinib 100 mg per day plus quercetin 1,000 mg per daythree consecutive days per week over 3 weeks, repeated across three 7-week cycles

   Dasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial · Nature metabolism · 1 Oct 2026

Cellular senescence →

1. Dasatinib + quercetin decreases metabolic dysfunction-associated steatohepatitis in humans (-1.43 ± 1.22 versus -0.39 ± 0.77).

   Human trialfibrotic MASHliverdasatinib 100 mg per day plus quercetin 1,000 mg per daythree consecutive days per week over 3 weeks, repeated across three 7-week cycles

   Dasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial · Nature metabolism · 1 Oct 2026

Metabolic dysfunction-associated steatohepatitis →

1. Dasatinib + quercetin decreases fibrotic metabolic dysfunction-associated steatohepatitis in humans (47% versus 7%).

   Human trialfibrotic MASHliverdasatinib 100 mg per day plus quercetin 1,000 mg per daythree consecutive days per week over 3 weeks, repeated across three 7-week cycles

   Dasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial · Nature metabolism · 1 Oct 2026

Fibrotic metabolic dysfunction-associated steatohepatitis →